TRexBio Announces Closing of Initial Public Offering

All shares in the offering were sold by TRexBio, with underwriting discounts, commissions and offering expenses deducted from gross proceeds.

Rhea-AI Summary

TRexBio (TRXB) closed its initial public offering, raising approximately $116.7 million in gross proceeds from shares sold by the company.

The offering comprised 8,333,334 common shares at $14.00 per share. Gross proceeds are before underwriting discounts, commissions and other offering expenses. The common stock is listed on the Nasdaq Global Select Market under TRXB. J.P. Morgan, Evercore ISI, Cantor and Stifel acted as lead book-running managers, with Wedbush PacGrow as book-running manager.

1 point · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 2 points

How the balance works

Positive

• Major pointCompleted IPO raised approximately $116.7 million in gross proceeds for TRexBio. 31% of market cap

Negative

• Major pointIssuance of 8,333,334 common shares at $14.00 per share dilutes existing shareholders.
• Minor pointUnderwriting discounts, commissions and offering expenses reduce proceeds retained by TRexBio.

Key Figures

Shares sold: 8,333,334 shares Offering price: $14.00 per share Gross proceeds: approximately $116.7 million

Shares sold

8,333,334 shares

Initial public offering; all shares sold by TRexBio

Offering price

$14.00 per share

Initial public offering

Gross proceeds

approximately $116.7 million

Before underwriting discounts, commissions, and other offering expenses

Key Terms

underwriting discounts, registration statement

2 terms

underwriting discounts financial

"before deducting underwriting discounts and commissions"

The portion of a securities offering that underwriters keep as payment for arranging and selling the issue, often expressed as the gap between what the issuer receives and the price paid by public investors. It matters to investors because it reduces the net proceeds the company raises and signals how much institutional middlemen are charging — like a broker’s commission — which can affect a deal’s economics and the degree of dilution for existing shareholders.

registration statement regulatory

"A registration statement (File No. 333-299018) relating to the shares"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced the closing of its initial public offering of 8,333,334 shares of its common stock at the initial public offering price of $14.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, was approximately $116.7 million. All of the shares were sold by TRexBio. TRexBio’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “TRXB”.

J.P. Morgan, Evercore ISI, Cantor, and Stifel are acting as lead book-running managers for the offering. Wedbush PacGrow is acting as book-running manager for the offering.

A registration statement (File No. 333-299018) relating to the shares sold in the offering has been filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on October 8, 2026. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from: J.P. Morgan Securities LLC, Attention Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; and Evercore Group L.L.C., 55 East 52nd Street, 35th Floor, New York, New York 10055, Attention: Equity Capital Markets, or by email at ecm.prospectus@evercore.com, or by telephone at (888) 474-0200.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About TRexBio
TRexBio is a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio’s Deep Biology Platform decodes Treg functionality in human tissue, mapping key drivers of immune dysregulation and uncovering novel targets and insights that inform drug discovery and translational efforts. This platform has generated multiple therapeutic development candidates across TRexBio’s wholly owned pipeline and through collaborations with leading pharmaceutical partners. TRexBio is led by an experienced management team and headquartered in South San Francisco, California.

Contacts

Investors: Laura Berner, Chief Operating Officer, TRex Bio, Inc., info@trex.bio

Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did TRexBio raise in its IPO?

TRexBio raised approximately $116.7 million in gross proceeds through its completed initial public offering. That amount is before underwriting discounts, commissions and other offering expenses.

What was TRexBio's IPO price and how many shares were sold?

TRexBio sold 8,333,334 common shares at $14.00 per share in its initial public offering. All shares were sold by the company.